NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Cancer Gene Therapy Week


Susan Hasty, Publisher
Table of Contents . . . November 24th, 2008
Non-Subscriber - Summaries Only
Related Areas: Other Issues in Cancer Gene Therapy Week | Other Publications

Fusion Proteins - Studies from H.S.R. Kotturi et al add new findings in the area of fusion proteins

Gene Therapy - New findings from Nanjing Medical University in the area of gene therapy described

Gene Therapy - New gene therapy study results reported from L.L. Zhou et al

Gene Therapy - Researchers at Osaka University publish new data on gene therapy

Life Sciences - Researchers from University of Pittsburgh describe findings in life sciences

Bone Research - New findings from Musculoskeletal Disease Center in the area of bone research published

Cancer Gene Therapy - New cancer gene therapy study results reported from Suzhou University

Cancer Gene Therapy - Studies in the area of cancer gene therapy reported from INSERM

Biotech Business - Morgenthaler Closes Ninth Fund at $400 Million



Return to Top of Page

-----------------------
PR Login